Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors

Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors

BackgroundImmune checkpoint inhibitors (ICIs) have revolutionised the cancer treatment landscape in the last decades, improving the outcome of several tumours, such as cutaneous squamous cell carcinoma (cSCC). ICIs are antibodies blocking several immune checkpoint pathways, as cytotoxic T lymphocyte...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna Arecco, Cristian Petolicchio, Alessandro Pastorino, Enrica Teresa Tanda, Lara Vera, Mara Boschetti, Francesco Cocchiara, Davide Carlo Maggi, Diego Ferone, Federico Gatto
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Endocrinology
Subjects:
immune checkpoint inhibitors
cemiplimab
diabetic ketoacidosis
immune-related adverse events
diabetes mellitus
anti-PD-1 monoclonal antibody
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1550702/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2025.1550702/full

Similar Items